These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 17418289

  • 21. Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention.
    Pels K, Schröder J, Witzenbichler B, Müller D, Morguet A, Pauschinger M, Schultheiss HP, Arntz HR.
    Eur J Emerg Med; 2008 Dec; 15(6):324-9. PubMed ID: 19078834
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Impact of abciximab on prognosis in diabetic patients undergoing primary percutaneous coronary intervention.
    Perkan A, Vitrella G, Barbati G, De Monte A, D'Agata B, Merlo M, Giannini F, Della Grazia E, Rakar S, Salvi A, Igidbashian D, Morgera T, Zalukar W, Sinagra G.
    J Cardiovasc Med (Hagerstown); 2013 Feb; 14(2):127-35. PubMed ID: 22343257
    [Abstract] [Full Text] [Related]

  • 25. Short- and long-term recovery of left ventricular function predicted at the time of primary percutaneous coronary intervention in anterior myocardial infarction.
    Bax M, de Winter RJ, Schotborgh CE, Koch KT, Meuwissen M, Voskuil M, Adams R, Mulder KJ, Tijssen JG, Piek JJ.
    J Am Coll Cardiol; 2004 Feb 18; 43(4):534-41. PubMed ID: 14975460
    [Abstract] [Full Text] [Related]

  • 26. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study.
    Rakowski T, Zalewski J, Legutko J, Bartus S, Rzeszutko L, Dziewierz A, Sorysz D, Bryniarski L, Zmudka K, Kaluza GL, Dubiel JS, Dudek D.
    Am Heart J; 2007 Mar 18; 153(3):360-5. PubMed ID: 17307412
    [Abstract] [Full Text] [Related]

  • 27. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.
    van 't Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, Petronio S, Marcel Gosselink AT, Jap W, Hollak F, Hoorntje JC, Suryapranata H, Dambrink JH, Zijlstra F, On-TIME study group.
    Eur Heart J; 2004 May 18; 25(10):837-46. PubMed ID: 15140531
    [Abstract] [Full Text] [Related]

  • 28. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF.
    Coron Artery Dis; 2008 Jun 18; 19(4):271-7. PubMed ID: 18480672
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Rescue use of abciximab improves regional left ventricular function after early incomplete reperfusion in acute myocardial infarction.
    Cho GY, Lee CW, Hong MK, Kang DH, Song JK, Kim JJ, Park SW, Park SJ.
    Clin Cardiol; 2001 Mar 18; 24(3):197-201. PubMed ID: 11288964
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
    Tödt T, Sederholm-Lawesson S, Stenestrand U, Alfredsson J, Janzon M, Swahn E.
    Acute Card Care; 2010 Mar 18; 12(1):10-7. PubMed ID: 20201657
    [Abstract] [Full Text] [Related]

  • 37. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
    Montalescot G, Borentain M, Payot L, Collet JP, Thomas D.
    JAMA; 2004 Jul 21; 292(3):362-6. PubMed ID: 15265852
    [Abstract] [Full Text] [Related]

  • 38. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW, CADILLAC Investigators.
    Circulation; 2003 Sep 16; 108(11):1316-23. PubMed ID: 12939213
    [Abstract] [Full Text] [Related]

  • 39. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI.
    Romagnoli E, Burzotta F, Trani C, Mazzari MA, Biondi-Zoccai GG, De Vita M, Giannico F, Niccoli G, Prati F, Rebuzzi AG, Mongiardo R, Crea F.
    Int J Cardiol; 2005 Dec 07; 105(3):250-5. PubMed ID: 16274764
    [Abstract] [Full Text] [Related]

  • 40. Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial.
    Prasad A, Stone GW, Aymong E, Zimetbaum PJ, McLaughlin M, Mehran R, Garcia E, Tcheng JE, Cox DA, Grines CL, Gersh BJ, CADILLAC trial.
    Am Heart J; 2004 Apr 07; 147(4):669-75. PubMed ID: 15077083
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.